Christina S Meade1, Sheri L Towe2, Melissa H Watt3, Ryan R Lion4, Bronwyn Myers5, Donald Skinner6, Stephen Kimani7, Desiree Pieterse8. 1. Duke University School of Medicine, Department of Psychiatry & Behavioral Sciences and Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: christina.meade@duke.edu. 2. Duke University School of Medicine, Department of Psychiatry & Behavioral Sciences and Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: sheri.towe@duke.edu. 3. Duke University, Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: melissa.watt@duke.edu. 4. Duke University, Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: ryan.lion@duke.edu. 5. Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Box 19070, Tygerberg 7505, South Africa. Electronic address: bronwyn.myers@mrc.ac.za. 6. Stellenbosch University, Faculty of Medicine and Health Sciences, Box 19063, Tygerberg 7505, South Africa. Electronic address: dskinner@sun.ac.za. 7. Duke University, Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: stephen.kimani@duke.edu. 8. Stellenbosch University, Faculty of Medicine and Health Sciences, Box 19063, Tygerberg 7505, South Africa. Electronic address: dpieterse2014@gmail.com.
Abstract
BACKGROUND: Since 2000, there has been a dramatic increase in methamphetamine use in South Africa, but little is known about the experiences of out-of-treatment users. This mixed-methods study describes the substance use histories, addiction symptoms, and treatment experiences of a community-recruited sample of methamphetamine users in Cape Town. METHODS: Using respondent driven sampling, 360 methamphetamine users (44% female) completed structured clinical interviews to assess substance abuse and treatment history and computerized surveys to assess drug-related risks. A sub-sample of 30 participants completed in-depth interviews to qualitatively explore experiences with methamphetamine use and drug treatment. RESULTS: Participants had used methamphetamine for an average of 7.06 years (SD=3.64). They reported using methamphetamine on an average of 23.49 of the past 30 days (SD=8.90); 60% used daily. The majority (90%) met ICD-10 criteria for dependence, and many reported severe social, financial, and legal consequences. While only 10% had ever received drug treatment, 90% reported that they wanted treatment. In the qualitative interviews, participants reported multiple barriers to treatment, including beliefs that treatment is ineffective and relapse is inevitable in their social context. They also identified important motivators, including desires to be drug free and improve family functioning. CONCLUSION: This study yields valuable information to more effectively respond to emerging methamphetamine epidemics in South Africa and other low- and middle-income countries. Interventions to increase uptake of evidence-based services must actively seek out drug users and build motivation for treatment, and offer continuing care services to prevent relapse. Community education campaigns are also needed.
BACKGROUND: Since 2000, there has been a dramatic increase in methamphetamine use in South Africa, but little is known about the experiences of out-of-treatment users. This mixed-methods study describes the substance use histories, addiction symptoms, and treatment experiences of a community-recruited sample of methamphetamine users in Cape Town. METHODS: Using respondent driven sampling, 360 methamphetamine users (44% female) completed structured clinical interviews to assess substance abuse and treatment history and computerized surveys to assess drug-related risks. A sub-sample of 30 participants completed in-depth interviews to qualitatively explore experiences with methamphetamine use and drug treatment. RESULTS:Participants had used methamphetamine for an average of 7.06 years (SD=3.64). They reported using methamphetamine on an average of 23.49 of the past 30 days (SD=8.90); 60% used daily. The majority (90%) met ICD-10 criteria for dependence, and many reported severe social, financial, and legal consequences. While only 10% had ever received drug treatment, 90% reported that they wanted treatment. In the qualitative interviews, participants reported multiple barriers to treatment, including beliefs that treatment is ineffective and relapse is inevitable in their social context. They also identified important motivators, including desires to be drug free and improve family functioning. CONCLUSION: This study yields valuable information to more effectively respond to emerging methamphetamine epidemics in South Africa and other low- and middle-income countries. Interventions to increase uptake of evidence-based services must actively seek out drug users and build motivation for treatment, and offer continuing care services to prevent relapse. Community education campaigns are also needed.
Authors: B Ustün; W Compton; D Mager; T Babor; O Baiyewu; S Chatterji; L Cottler; A Göğüş; V Mavreas; L Peters; C Pull; J Saunders; R Smeets; M R Stipec; R Vrasti; D Hasin; R Room; W Van den Brink; D Regier; J Blaine; B F Grant; N Sartorius Journal: Drug Alcohol Depend Date: 1997-09-25 Impact factor: 4.492
Authors: Wendee M Wechsberg; Hendree E Jones; William A Zule; Bronwyn J Myers; Felicia A Browne; Michelle R Kaufman; Winnie Luseno; Alan J Flisher; Charles D H Parry Journal: Am J Drug Alcohol Abuse Date: 2010-07 Impact factor: 3.829
Authors: L N Robins; J Wing; H U Wittchen; J E Helzer; T F Babor; J Burke; A Farmer; A Jablenski; R Pickens; D A Regier Journal: Arch Gen Psychiatry Date: 1988-12
Authors: Soraya Seedat; D J Stein; A Herman; R Kessler; J Sonnega; S Heeringa; S Williams; D Williams Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2008-08-02 Impact factor: 4.328
Authors: Kathryn E Lancaster; Vivian F Go; Thandie Lungu; Pearson Mmodzi; Mina C Hosseinipour; Katy Chadwick; Kimberly A Powers; Brian W Pence; Irving F Hoffman; William C Miller Journal: Int J Drug Policy Date: 2016-02-26
Authors: Christina S Meade; Ryan R Lion; Daniella M Cordero; Melissa H Watt; John A Joska; Hetta Gouse; Warren Burnhams Journal: AIDS Behav Date: 2016-10
Authors: Fleur L Warton; Ernesta M Meintjes; Christopher M R Warton; Christopher D Molteno; Nadine M Lindinger; R Colin Carter; Lilla Zöllei; Pia Wintermark; Joseph L Jacobson; Andre van der Kouwe; Sandra W Jacobson Journal: Neurotoxicol Teratol Date: 2017-10-22 Impact factor: 3.763
Authors: Fleur L Warton; Paul A Taylor; Christopher M R Warton; Christopher D Molteno; Pia Wintermark; Nadine M Lindinger; Lilla Zöllei; Andre van der Kouwe; Joseph L Jacobson; Sandra W Jacobson; Ernesta M Meintjes Journal: Metab Brain Dis Date: 2017-10-23 Impact factor: 3.584
Authors: Jessica F Magidson; John A Joska; Kristen S Regenauer; Emily Satinsky; Lena S Andersen; C J Seitz-Brown; Christina P C Borba; Steven A Safren; Bronwyn Myers Journal: Int J Drug Policy Date: 2019-05-10